 Home > Active Ingredient News > Antitumor Therapy > NEJM: Levatinib-Pembrolizumab is better than sunitinib in the treatment of advanced renal cell carcinoma

NEJM: Levatinib-Pembrolizumab is better than sunitinib in the treatment of advanced renal cell carcinoma

 Last Update: 2021-04-17
 Source: Internet
 Author: User

Tags

3 day detox

everolimus mechanism action

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Sunitinib and other vascular endothelial growth factor receptor tyrosine kinase inhibitors are the first-line treatment for patients with advanced renal cell carcinoma, but most patients have relapsed due to the development of drug resistance.

Sunitinib vascular

Recently, researchers investigated the therapeutic effect of tyrosine kinase inhibitor levatinib combined with PD-1 monoclonal antibody pembrolizumab or levatinib combined with everolimus on advanced renal cell carcinoma .

In this phase III clinical study, patients with advanced renal cell carcinoma who have not received systemic treatment in the past were randomized to receive levatinib (20 mg orally per day) combined with pembrolizumab (200 mg intravenously every 3 weeks), levatinib Ninetil (18 mg orally per day) combined with everolimus (5 mg orally per day) or sunitinib (50 mg orally once a day, once every 4 weeks, taking the drug for 2 consecutive weeks, and then stopping the drug for 2 weeks).

A total of 1069 patients participated in the study, including 355 in the levatinib-pembrolizumab group, 357 in the levatinib-everolimus group, and 357 in the sunitinib group.

Le Laval imatinib - progression-free survival of patients Paim monoclonal set longer than the sunitinib group (median 23.

The study found that for patients with advanced renal cell carcinoma, levatinib-pembrolizumab treatment has a significant advantage compared with sunitinib in improving the progression-free survival and overall survival of patients.

For patients with advanced renal cell carcinoma, levatinib-pembrolizumab treatment has a significant advantage compared with sunitinib in improving the progression-free survival and overall survival of patients.

Original source:

Robert Motzer et al.

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.